Filing Flows › Health Care › Orthopediatrics (KIDS)
Orthopediatrics (KIDS) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Oct 28, 2026 · Orthopediatrics (KIDS) Q3 2026 earnings results →
Q3 2026 Revenue up 19% year over year to $72.7M · 8¢ of every $1 of revenue lost · operating margin -5.8%
Orthopediatrics made $72.7M in Q3 2026 (+19% Y/Y): Trauma and deformity $52.6M, Scoliosis $19.2M, Sports medicine/other $866K. Operating margin -5.8%, net loss $5.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 28, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $72.7M in Q3 2026, up 19% year over year and up 3% from the previous quarter. Trauma and deformity was the largest line at 72% of revenue. Trauma and deformity added $8.5M year over year (up 19%), 74% of the total change.
Gross margin was 74.3%, up 0.4 points from Q3 2025. Operating costs exceeded revenue by $4.2M, an operating margin of -5.8%. Operating expenses grew 6% against revenue growth of 19%. The fastest-growing cost line was Sales & marketing (+24%). The quarter ended with a net loss of $5.9M, narrower than the previous quarter's $7.2M loss.
Operating cash flow was $4.5M. Non-cash charges added back $5.6M of depreciation and amortization and $4.4M of share-based compensation. Working capital and other items added $396K. Capital expenditures of $2.9M left free cash flow of $1.6M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Oct 28, 2026 | $72.7M | +19% | -5.8% | −$5.9M | $4.5M |
| Q2 2026 | 10-Q | Aug 5, 2026 | $70.5M | +15% | -5.8% | −$7.2M | $928K |
| Q1 2026 | 10-Q | May 1, 2026 | $59.4M | +13% | -14.0% | −$10.7M | −$3.3M |
| Q4 2025 | 10-K | Mar 4, 2026 | $61.6M | +17% | -13.3% | −$10.1M | $10.3M |
| Q3 2025 | 10-Q | Oct 29, 2025 | $61.2M | +12% | -15.4% | −$11.8M | −$581K |
| Q2 2025 | 10-Q | Aug 6, 2025 | $61.1M | +16% | -17.4% | −$7.1M | −$10.5M |
| Q1 2025 | 10-Q | May 8, 2025 | $52.4M | +17% | -21.0% | −$10.7M | −$4.2M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Orthopediatrics
OrthoPediatrics Corp. (the "Company") is a Delaware corporation, headquartered in Warsaw, Indiana, and organized in November 2007. The Company’s Common Stock is traded on the Nasdaq Global Market under the symbol KIDS. OrthoPediatrics Corp. is a medical device company committed to designing, developing and marketing anatomically appropriate implants, instruments and specialized braces for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. Initially organized as an Indiana limited liability company on August 31, 2006, OrthoPediatrics Corp. was converted to a Delaware corporation on November 30, 2007.
In its own words, from its 10-K, filed Mar 4, 2026.
Orthopediatrics against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +19% against the peers' median +5%. Operating margin: -5.8% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| KIDS Orthopediatrics | Q3 2026 | $72.7M | +19% | -5.8% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Orthopediatrics 10-Q on SEC EDGAR · CIK 1425450 · Surgical & Medical Instruments & Apparatus
13F: who owns KIDS and who is buying
More on KIDS
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results